Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

• Manuel Sánchez Cánovas ^[11] ; David Fernández Garay ^[1] ; Evdochia Adoamnei ^[2] ; Esperanza Guirao García ^[11] ; Javier López Robles ^[11] ; Diego Cacho Lavin ^[3] ; Eva Martínez de Castro ^[3] ; Begoña Campos Balea ^[4] ; Alberto Garrido Fernández ^[12] ; Isaura Fernández Pérez ^[12] ; Asia Ferrández Arias ^[5] ; Noelia Suarez ^[5] ; Teresa Quintanar Verduguez ^[5] ; Miriam Lobo de Mena ^[6] ; Laura Rodríguez ^[7] ; David Gutierrez ^[7] ; Ana Manuela Martín Fernández de Soiginie ^[7] ; Silvia García Adrián ^[8] ; Ana Isabel Ferrer Pérez ^[9] ; María Jesús Delgado Heredia ^[10] ; Amelia Muñoz Lerma ^[13] ; Raquel Luque ^[13] ; Manuel Mazariegos Rubí ^[14] ; Ana Belen Rúperez Blanco ^[14] ; Ignacio García Escobar ^[14] ; Jaime Mendiola ^[2] ; Andrés Jesús Muñoz Martín ^[15]
  1. [1] Hospital Costa Del Sol

     Hospital Costa Del Sol

     Marbella, España

     
  2. [2] Universidad de Murcia

     Universidad de Murcia

     Murcia, España

     
  3. [3] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  4. [4] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  5. [5] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  6. [6] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  7. [7] Hospital de Fuenlabrada

     Hospital de Fuenlabrada

     Fuenlabrada, España

     
  8. [8] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  9. [9] Hospital Obispo Polanco

     Hospital Obispo Polanco

     Teruel, España

     
  10. [10] Hospital Universitario de la Princesa

      Hospital Universitario de la Princesa

      Madrid, España

      
  11. [11] Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, España
  12. [12] Departamento de Oncología Médica, Hospital Álvaro Cunqueiro-Complejo Hospitalario Universitario de Vigo, Vigo, España
  13. [13] Servicio de Oncología Médica, Hospital Virgen de las Nieves, Granada, España
  14. [14] Departamento de Oncología Médica, Hospital Universitario de Toledo, Toledo, España
  15. [15] Departamento de Oncología Médica, Hospital Universitario Gregorio Marañón, Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 10 (October), 2023, págs. 3021-3031
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice.

    Methods/patients Retrospective, multicenter study promoted by the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM). Individuals with kidney or bladder cancer who initiated ICI between 01/01/2015 and 12/31/2020 were recruited. Minimum follow-up was 6 months (except in cases of demise). The primary objective was to calculate the incidence of ICI-associated VTE/AT and secondary objectives included to analyze their impact on survival and identify variables predictive of VTE/AT.

    Results 210 patients with kidney cancer were enrolled. The incidence of VTE/AT during follow-up (median 13 months) was 5.7%. Median overall survival (OS) was relatively lower among subjects with VTE/AT (16 months, 95% CI 0.01–34.2 vs. 27 months, 95% CI 22.6–31.4; p = 0.43). Multivariate analysis failed to reveal predictive variables for developing VTE/ AT.

    197 patients with bladder were enrolled. There was a 9.1% incidence rate of VTE/AT during follow-up (median 8 months). Median OS was somewhat higher in patients with VTE/AT (28 months, 95% CI 18.4–37.6 vs 25 months, 95% CI 20.7–29.3; p = 0.821). Serum albumin levels < 3.5 g/dl were predictive of VTE/ AT (p < 0.05).

    Conclusions There appears to be no association between developing VTE/AT and ICI use in patients with renal or bladder cancer. Serum albumin levels are a predictive factor in individuals with bladder cancer.